Trump Threatens 100% Tariffs on US Drug Makers Refusing to Lower Prices

President Donald Trump has announced a new policy threatening to impose 100% tariffs on US pharmaceutical companies that do not agree to lower their drug prices. This move is part of his effort to address the high cost of prescription medications in the US.

The tariffs will specifically target branded drugs and their active ingredients, while generic drugs, which account for over 90% of medicines sold in the US, will be exempt for at least one year. Additionally, certain specialty drugs, such as orphan, veterinary, and other specialty drugs, will be exempt if they are from countries with which the US has a trade deal or meet urgent public health needs.

Drugmakers that enter into pricing agreements with the White House and onshore drug production will be exempt from the tariffs. Companies planning to increase their domestic manufacturing will face a 20% tariff that will escalate to 100% over four years.

The policy has been met with criticism from industry groups, such as the Midsized Biotech Alliance of America (MBAA), which argues that it creates an "unfair two-tiered system" that benefits large companies with diversified portfolios.

Trump has been under pressure to lower drug prices, with US patients often paying nearly triple what patients pay in other developed nations. The announcement comes as the White House faces pressure from consumers to address rising costs amid other tariff-related price increases and high gas prices triggered by geopolitical tensions.